Organon & Co. (OGN) to Release Earnings on Thursday

Organon & Co. (NYSE:OGN) is expected to be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect Organon & Co. to post earnings of $0.92 per share and revenue of $1.53 billion for the quarter. Organon & Co. has set its FY 2025 guidance at EPS.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Trading Up 2.2 %

Shares of OGN opened at $11.49 on Thursday. The stock’s fifty day simple moving average is $13.99 and its 200-day simple moving average is $15.27. The firm has a market capitalization of $2.96 billion, a PE ratio of 3.45, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. Organon & Co. has a 12-month low of $10.45 and a 12-month high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were issued a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 9.75%. Organon & Co.’s dividend payout ratio is currently 33.63%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays dropped their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Finally, Morgan Stanley reduced their price target on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Organon & Co. has an average rating of “Hold” and a consensus price target of $20.60.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.